Newamsterdam Pharma Co Nv (NAMS)$35.44
Market Cap: 2.22 BCurrency: USD
Research Snapshot
Static fundamentals, valuation context, and investor signals for Newamsterdam Pharma Co Nv (NAMS).
HEALTHCARE
BIOTECHNOLOGY
DCF ready
Valuation
-11.7x
EV/FCF, N/A FCF yield
Quality
-29.7%
ROIC, -657.8% FCF margin
Growth
N/A
5Y sales (revenue) CAGR
Balance sheet
0.0x
Debt/equity, 7.9x current ratio
Superinvestors
2
Top: Lee Ainslie (0.8%)
Strengths to research
- Debt/equity looks manageable at 0.0x.
Watchouts
- Free cash flow margin is negative at -657.8%.
Annual data: 5 periods
Quarterly data: 12 periods
Stock snapshot: May 25, 2026
Static dataset: May 25, 2026
Quality Scorecard
Build-time composite score for NAMS.
Grade F
2
/ 100
Peer Comparison
Target stock against 8 market-cap comparable peers.
Heat map: red worst to green best
| NAMS Target | Newamsterdam Pharma Co Nv | $2.2B | -20.6x | -11.7x | -29.7% | N/A | -657.8% | N/A | N/A | N/A |
| IMVT | Immunovant Inc. | $2.6B | -12.3x | -4.1x | -59.3% | N/A | N/A | N/A | N/A | N/A |
| TVTX | Travere Therapeutics Inc. | $1.9B | -153.2x | 47.9x | -22.2% | 19.9% | 7.7% | N/A | N/A | N/A |
| EWTX | Edgewise Therapeutics Inc. | $1.7B | -20.1x | -11.6x | -0.0% | N/A | N/A | N/A | N/A | N/A |
| ADPT | Adaptive Biotechnologies Corp. | $1.5B | -35.6x | -29.7x | -27.2% | 23.0% | -17.7% | N/A | N/A | N/A |
| MESO | Mesoblast Ltd Spon ADR | $1.4B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| PCVX | Vaxcyte Inc. | $4.4B | -8.4x | -6.3x | -0.0% | N/A | N/A | N/A | N/A | N/A |
| PHVS | Pharvaris NV | $1.0B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| IONS | Ionis Pharmaceuticals Inc. | $5.4B | -31.7x | -21.2x | -16.6% | 5.3% | -33.9% | N/A | N/A | N/A |
Financial Charts
No financial data available for NAMS (annual).
2 superinvestors own NAMS
Current quarter ownership and quarter-over-quarter share changes.
Superinvestor ownership
| Fund | Shares | Value | % Portfolio | QoQ Change |
|---|---|---|---|---|
| Viking Global Investors Viking Global Investors | 4,203,567 | $135M | 0.38% | 0.0% |
| Lee Ainslie Maverick Capital | 2,186,402 | $70M | 0.81% | 0.0% |